The prognostic value of biomarkers after a premature myocardial infarction

International Journal of Cardiology

Volumn 143, Issue 3, 2010, Pages 249-254

  Pineda, Javier ^a   Marín, Francisco ^a,c   Marco, Pascual ^a   Roldán, Vanessa ^b   Valencia, José ^a   Ruiz Nodar, Juan Miguel ^a   Romero, Diana Hernández ^c   Sogorb, Francisco ^a   Lip, Gregory Y H ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Coronary risk factors; Prognostic markers; Young myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL DAMAGE; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTION; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SMOKING; THROMBOGENESIS; THROMBOPHILIA;

ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA;

EID: 77956570459     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.02.019     Document Type: Article

References (55)

1. M. Naghavi, P. Libby, and E. Falk From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I Circulation 108 2003 1664 1672 (Pubitemid 37243650)
2. L.S. Rallidis, J. Lekakis, and D. Panagiotakos Long-term prognostic factors of young patients (≤ 35 years) having acute myocardial infarction: the detrimental role of continuation of smoking Eur J Cardiovasc Prev Rehabil 15 2008 567 571
3. J. Pineda, F. Marín, V. Roldán, J. Valencia, P. Marco, and F. Sogorb Premature myocardial infarction: clinical profile and angiographic findings Int J Cardiol 126 2008 127 129
4. L. Choudhury, and J. Marsh Myocardial infarction in young patients Am J Med 107 1999 254 261
5. T. Moccetti, R. Malacrida, and E. Pasotti Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. The GISSI investigators Arch Intern Med 157 1997 865 869
6. J.H. Cole, J.I. Miller, L.S. Sperling, and W.S. Weintraub Long-term follow-up of coronary artery disease presenting in young adults J Am Coll Cardiol 41 2003 521 528
7. D. Mukherjee, A. Hsu, D.J. Moliterno, A.M. Lincoff, M. Goormastic, and E.J. Topol Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients ≤ 40 years old Am J Cardiol 92 2003 1465 1467
8. F. Zimmerman, A. Cameron, and L. Fisher Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Surgery Study Registry) J Am Coll Cardiol 26 1995 654 661
9. S. Osula, G.M. Bell, and R.S. Hornung Acute myocardial infarction in young adults: causes and management Postgrad Med J 78 2002 27 30
10. D.G. Hackam, and S.S. Anand Emerging risk factors for atherosclerotic vascular disease JAMA 290 2003 932 940
11. Joint European Society of Cardiology/American College of Cardiology Committee Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology Committee for the redefinition of myocardial infarction Eur Heart J 21 2000 1502 1513
12. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on standarization of clinical nomenclature Circulation 59 1979 607 609
13. A. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 Report JAMA 289 2003 2560 2572 (Pubitemid 37430158)
14. Third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Circulation 106 2002 3143 3421
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 20 1997 1183 1197
16. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
17. A. Clauss Schnellmethode zur Bestimmung des fibrinogens Acta Haematol 17 1957 237 247
18. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention Eur Heart J 19 1998 1434 1503
19. D.M. Lloyd-Jones, E.P. Leip, and M.G. Larson Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
20. J. Milei, and D.R. Grana Mortality and morbidity from smoking-induced cardiovascular diseases: the necessity of the cardiologist's involvement and commitment Int J Cardiol 67 1998 95 109
21. J.B. Cavender, W.S. Rogers, L.D. Fisher, B.J. Gersh, C.J. Coggin, and W.O. Myers Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the coronary artery surgery study (CASS); 10 years follow-up J Am Coll Cardiol 20 1992 287 294
22. T.D. Rea, S.R. Heckbert, R.C. Kaplan, N.L. Smith, R.N. Lemaitre, and B.M. Psaty Smoking status and risk for recurrent coronary events after myocardial infarction Ann Intern Med 137 2002 494 500
23. K. Wilson, N. Gibson, A. Willan, and D. Cook Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies Arch Intern Med 160 2000 939 944
24. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
25. T.F.M. Van Berkel, H. Boersma, J.W. Roos-Hesselink, R.A.M. Erdman, and M.L. Simoons Impact of smoking cessation and smoking interventions in patients with coronary heart disease Eur Heart J 20 1999 1773 1782
26. E. Arbustini, M. Grasso, and M. Diegoli Coronary thrombosis in non-cardiac death Coron Artery Dis 4 1993 751 759
27. S. Kaul, A.A. Zadeh, and P.K. Shah Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated J Am Coll Cardiol 48 2006 914 923
28. P.M. Ridker, N.J. Brown, D.E. Vaughan, D.G. Harrison, and J.L. Mehta Established and emerging plasma biomarkers in the prediction of first atherothrombotic events Circulation 109 Suppl IV 2004 6 19
29. O. Nygard, J.E. Nordrehaug, H. Refsum, P.M. Ueland, M. Farstad, and S.E. Vollset Plasma homocysteine levels and mortality in patients with coronary artery disease N Engl J Med 337 1997 230 236 (Pubitemid 27310438)
30. J.L. Anderson, J.B. Muhlestein, and B.D. Horne Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease Circulation 102 2000 1227 1232
31. R.J. Gibbons, K. Chatterjee, and J. Daley ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the ACC/AHA Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina) J Am Coll Cardiol 33 1999 2097 2197
32. J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
33. K.V. Phadke, R.A. Phillips, D.T. Clarke, M. Jones, P. Naish, and P. Carson Anticardiolipin antibodies in ischaemic heart disease: marker or myth? Br Heart J 69 1993 391 394
34. M. Cortellaro, C. Voschetti, M. Cardilo, and T. Barbui Antiphospholipid antibodies in patients with previous myocardial infarction Lancet 339 1992 929 930
35. K.E. Sletnes, P. Smith, M. Abdelnoor, H. Arnesen, and F. Wisloff Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke Lancet 339 1992 451 453
36. R.A. Asherson, M.A. Khamashta, E. Baguley, C.M. Oakley, N.M. Rowell, and G.R. Hughes Myocardial infarction and antophospholipid antibodies in SLE and related disorders Q J Med 272 1989 1103 1115
37. E. Zuckerman, E. Toubi, and A. Shiran Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study Am J Med 171 1996 381 386
38. A. Hamsten, M. Björkholm, R. Norberg, U. de Faire, and G. Holm Antibodies to cardiolopin in young survivors of myocardial infarction: an association with recurrent cardiovascular events Lancet 1 1986 113 116
39. O. Vaarala, M. Manttari, V. Manninen, L. Tenkanen, M. Puurunen, and K. Aho Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men Circulation 91 1995 23 27
40. A.G. Olsson, G.G. Schwartz, and M. Szarek High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from de MIRACL trial Eur Heart J 26 2005 890 896
41. P. Barter, J. Kastelein, A. Nunn, and R. Hobbs High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions Atherosclerosis 168 2003 195 211
42. A. Moss, R. Goldstein, and V. Marder Thrombogenic factors and recurrent coronary events Circulation 99 1999 2517 2522
43. I. Juhan-Vague, S. Pyke, M. Alessi, J. Jerpersen, F. Haverkate, and S.G. Thompson Fibrinolytic factors and the risk of myocardial infaction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities Circulation 94 1996 2057 2063
44. M. Tataru, J. Heinrich, R. Junker, H. Schulte, A. von Eckardstein, and G. Assmann D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction Eur Heart J 20 1999 1493 1502
45. P.H. Whincup, J. Danesh, and M. Walker Von Willebrand factor and coronary heart disease. Prospective study and meta-analysis Eur Heart J 23 2002 1764 1770 (Pubitemid 35334269)
46. B. Wiman, T. Andersson, J. Hallqvist, C. Reuterwall, A. Ahlbom, and U. deFaire Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) Study Arterioscler Thromb Vasc Biol 20 2000 2019 2023
47. G. Lowe, J. Danesh, and S. Lewington Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis Eur Heart J 25 2004 252 259
48. J. Danesh, P. Whincup, and M. Walker Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses BMJ 321 2000 199 204
49. M.A. Mendall, D.P. Strachan, and B.K. Butland C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men Eur Heart J 21 2000 1584 1590
50. B. Lindahl, H. Toss, A. Siegbahn, P. Venge, and L. Wallentin Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group N Engl J Med 343 2000 1139 1147
51. J.S. Zebrack, J.B. Muhlestein, B.D. Horne, and J.L. Anderson C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina J Am Coll Cardiol 39 2002 632 637
52. A. Hoffmeister, D. Rothenbacher, U. Bäzner, M. Fröhlich, H. Brenner, and V. Hombach Role of novel markers of inflammation in patients with stable coronary heart disease Am J Cardiol 87 2001 262 266
53. M.A. Albert, E. Danielson, N. Rifai, and P.M. Ridker Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation CRP Evaluation (PRINCE) JAMA 286 2001 64 70
54. L. Szapáry, B. Horváth, Z. Márton, G. Fehér, K. Tóth, and S. Komoly Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients Orv Hetil 149 24 2008 1117 1123
55. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150